Map the field
Publications, trial records, press releases and pipelines covered preclinical to approved programs.
A top 20 pharmaceutical company wanted a global view of new targets, mechanisms and modalities in atopic dermatitis. We mapped 197 programs, interviewed 4 dermatology experts and selected 18 for deep dives.
The client is a top 20 international pharmaceutical company. It also wanted to find programs in Th2-mediated biology that might reach beyond atopic dermatitis.
Prescouter was asked to build a global landscape of novel and emerging targets, mechanisms of action and modalities in atopic dermatitis, including programs in Th2-mediated biology.
New biology in atopic dermatitis.
How each program works.
Programs with wider potential.
Publications, trial records, press releases and pipelines covered preclinical to approved programs.
Experts shared views on how atopic dermatitis is managed and where the field is heading.
We profiled the programs that best matched the client’s targets of interest.
Prescouter turned its research and expert insights into 5 reports covering 197 profiled programs. It selected 18 programs for deep dives based on the client’s targets of interest and delivered a roadmap of opportunities to guide strategic decisions.
Preclinical, clinical and approved.
Matched to targets of interest.
Ending in an opportunity roadmap.
In crowded therapeutic areas, the edge comes from seeing the whole field. A full map makes the best targets easier to spot.
Map the field, consult the experts and focus on the targets that matter. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]Pick a time on our calendar right now.
If you’d like to know the outcome of your submission, please leave your email address